COX-2 - IV
Meta-análise de J Zhang e col. na JAMA sobre efeitos renais e arrítmicos dos inibidores COX-2.
Meta-analysis by J Zhang et al. in JAMA on renal effects and arrhythmia risk of COX-2 inhibitors.
"...rofecoxib was associated with increased renal and arrhythmia risks. A COX-2 inhibitor class effect was not evident."
Meta-análise de P McGettigan & D Henry na JAMA sobre risco cardiovascular associado ao uso de inibidores COX-2.
Meta-analysis by P McGettigan & D Henry in JAMA on cardiovascular risk of COX-2 inhibitors.
"This review confirms the findings from randomized trials regarding the risk of cardiovascular events with rofecoxib and suggests that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug."
Editorial de/by DJ Graham.
Meta-analysis by J Zhang et al. in JAMA on renal effects and arrhythmia risk of COX-2 inhibitors.
"...rofecoxib was associated with increased renal and arrhythmia risks. A COX-2 inhibitor class effect was not evident."
Meta-análise de P McGettigan & D Henry na JAMA sobre risco cardiovascular associado ao uso de inibidores COX-2.
Meta-analysis by P McGettigan & D Henry in JAMA on cardiovascular risk of COX-2 inhibitors.
"This review confirms the findings from randomized trials regarding the risk of cardiovascular events with rofecoxib and suggests that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug."
Editorial de/by DJ Graham.
